49671-76-3

Basic information

• Product Name: ZLN005
• Synonyms: 2-(4-tert-Butylphenyl)-1H-benzimidazole;2-(4-tert-Butylphenyl)benzimidazole;2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole;2-(4-tert-Butylphenyl)benzimidazole ZLN005;ZLN005 2-(4-tert-Butylphenyl)benzimidazole;ZLN005, >=98%;ZLN005
• CAS NO: 49671-76-3
• Molecular Formula: C₁₇H₁₈N₂
• Molecular Weight: 250.33822
• Product Categories: Inhibitors
• Mol File: 49671-76-3.mol
• Article Data: 20

Chemical Properties

• Melting Point: 257-258℃
• Boiling Point: 415.3±38.0 °C(Predicted)
• Appearance: white to beige/
• Density: 1.102±0.06 g/cm3(Predicted)
• Storage Temp.: ?20°C
• Solubility: DMSO: soluble10mg/mL, clear
• PKA: 11.52±0.10(Predicted)
• CAS DataBase Reference: ZLN005(CAS DataBase Reference)
• NIST Chemistry Reference: ZLN005(49671-76-3)
• EPA Substance Registry System: ZLN005(49671-76-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 49671-76-3(Hazardous Substances Data)

Usage

Description

ZLN005 is a small molecule that acts as a potent stimulator of the expression of Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) and its downstream genes in skeletal muscle cells. It plays a crucial role in enhancing energy metabolism, hepatic gluconeogenesis, and cholesterol homeostasis, thereby improving glucose utilization and fatty acid oxidation.

Uses

Used in Pharmaceutical Applications:
ZLN005 is used as a therapeutic agent for improving glucose tolerance, pyruvate tolerance, and insulin sensitivity in diabetic individuals, particularly in db/db mice. The application reason is that it increases PGC-1α and downstream gene transcription in skeletal muscles, leading to enhanced fat oxidation and overall metabolic health.
Used in Metabolic Research:
ZLN005 is used as a research tool for studying the role of PGC-1α in energy metabolism, hepatic gluconeogenesis, and cholesterol homeostasis. The application reason is its ability to stimulate the expression of PGC-1α and downstream genes in skeletal muscle cells, providing valuable insights into the molecular mechanisms underlying these processes.
Used in Drug Development:
ZLN005 is used as a lead compound in the development of new drugs targeting metabolic disorders and diabetes. The application reason is its potential to improve glucose utilization and fatty acid oxidation, offering a promising therapeutic approach for managing these conditions.

Upstream product

• 939-97-9 4-tert-Butylbenzaldehyde 
• 95-54-5 1,2-diamino-benzene 
• 1042161-47-6 C₁₇H₁₈N₄ 
• 4857-06-1 2-chloro-1H-benzoimidazole 
• 123324-71-0 p-tert-butylphenylboronic acid 
• 615-43-0 2-iodophenylamine 
• 18880-00-7 1-(bromomethyl)-4-(1,1-dimethylethyl)benzene 
• 943-27-1 4'-t-butylacetophenone 
• 39895-55-1 4-(1,1-dimethylethyl)-benzenemethanamine 
• 88-74-4 2-nitro-aniline 
• 877-65-6 p-tert-butylbenzyl alcohol 

Relevant articles and documents

s-Tetrazine-functionalized hyper-crosslinked polymers for efficient photocatalytic synthesis of benzimidazoles

Developing green-safe, efficient and recyclable catalysts is crucial for the chemical industry. So far, organic photocatalysis has been proved to be an environmentally friendly and energy-efficient synthetic technology compared with traditional metal catalysis. As a versatile catalytic platform, hyper-crosslinked polymers (HCPs) with large surface area and high stability are easily prepared. In this report, we successfully constructed two porous HCP photocatalysts (TZ-HCPs) featurings-tetrazine units and surface areas larger than 700 m2g?1through Friedel-Crafts alkylation reactions. The rational energy-band structures and coexisting micro- and mesopores endow TZ-HCPs with excellent activities to realize the green synthesis of benzimidazoles (28 examples, up to 99% yield, 0.5-4.0 h) in ethanol. Furthermore, at least 21 iterative catalytic runs mediated by TZ-HCP1D were performed efficiently, with 96-99% yield. This study of TZ-HCPs sheds light on the wide-ranging prospects of application of HCPs as metal-free and green photocatalysts for the preparation of fine chemicals.

Visible-Light-Driven Sulfonylation/Cyclization to Access Sulfonylated Benzo[4,5]imidazo[2,1-a]isoquinolin-6(5H)-ones

Visible-light-driven sulfonylation/cyclization of N-methacryloyl-2-phenylbenzoimidazoles has been successfully developed. Using commercially available sulfonyl chloride as sulfonylation reagent, a wide range of sulfonylated benzo[4,5]imidazo[2,1-a]isoquinolin-6(5H)-ones with potential antitumor activity were provided in acceptable to excellent yields. This method has the advantages of mild reaction conditions and outstanding functional group tolerance, and provides a new strategy for the development of potential antitumor lead compounds.

Nickel catalyzed sustainable synthesis of benzazoles and purines: Via acceptorless dehydrogenative coupling and borrowing hydrogen approach

Herein we report nickel-catalyzed sustainable synthesis of a few chosen five-membered fused nitrogen heterocycles such as benzimidazole, purine, benzothiazole, and benzoxazole via acceptorless dehydrogenative functionalization of alcohols. Using a bench stable, easy to prepare, and inexpensive Ni(ii)-catalyst, [Ni(MeTAA)] (1a), featuring a tetraaza macrocyclic ligand (tetramethyltetraaza[14]annulene (MeTAA)), a wide variety of polysubstituted benzimidazole, purine, benzothiazole, and benzoxazole derivatives were prepared via dehydrogenative coupling of alcohols with 1,2-diaminobenzene, 4,5-diaminopyrimidine, 2-aminothiphenol, and 2-aminophenol, respectively. A wide array of benzimidazoles were also prepared via a borrowing hydrogen approach involving alcohols as hydrogen donors and 2-nitroanilines as hydrogen acceptors. A few control experiments were performed to understand the reaction mechanism.